132 results on '"Watabe, Akiko"'
Search Results
2. Specific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability by reduced Fc dynamics
3. Intracellular polyamine depletion induces N-linked galactosylation of the monoclonal antibody produced by CHO DP-12 cells
4. Target-independent Immune-cell Activation by Aggregates of T Cell-redirecting Bispecific Antibodies
5. Development of a penetratin-conjugated stapled peptide that inhibits Wnt/β-catenin signaling
6. A Collaborative Study on the Classification of Silicone Oil Droplets and Protein Particles Using Flow Imaging Method
7. Subvisible Particles Derived by Dropping Stress Enhance Anti-PEG Antibody Production and Clearance of PEGylated Proteins in Mice
8. Quantitative Evaluation of Insoluble Particulate Matters in Therapeutic Protein Injections Using Light Obscuration and Flow Imaging Methods
9. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
10. Characterization of Aggregated Antibody-Silicone Oil Complexes: From Perspectives of Morphology, 3D Image, and Fcγ Receptor Activation
11. Development of anti-drug monoclonal antibody panels against adalimumab and infliximab
12. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates
13. In-depth site-specific O-Glycosylation analysis of therapeutic Fc-fusion protein by electron-transfer/higher-energy collisional dissociation mass spectrometry
14. Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium
15. Interlaboratory comparison about feasibility of insoluble particulate matter test for injections with reduced test volume in light obscuration method
16. 2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)
17. Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design.
18. Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics
19. Genetic Polymorphisme of FCGRT Encoding FcRn in a Japanese Population and Their Functional Analysis
20. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 – hybrid LBA/LCMS, ELN & regulatory agencies’ input)
21. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 – LBA and immunogenicity)
22. Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant
23. The Novel Compounds That Activate Farnesoid X Receptor: the Diversity of Their Effects on Gene Expression
24. 2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)
25. Successful treatment of syringotropic CD8+ mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids
26. Caspase Cascade Proceeds Rapidly After Cytochrome c Release From Mitochondria in Tumor Necrosis Factor-α-Induced Cell Death
27. Evaluation of the analytical performance of anti-SARS-CoV-2 antibody test kits distributed or developed in Japan.
28. Site-specific N-glycosylation analysis of human plasma ceruloplasmin using liquid chromatography with electrospray ionization tandem mass spectrometry
29. Functional analysis of the Notch ligand Jagged1 missense mutant proteins underlying Alagille syndrome
30. Evaluation of intracellular trafficking and clearance from HeLa cells of doxorubicin-bound block copolymers
31. A comparison of the tube forming potentials of early and late endothelial progenitor cells
32. Interferon-α is effective for CD4+, CCR4– mycosis fungoides
33. Coexistence of vitiligo and sarcoidosis in a patient with circulating autoantibodies
34. Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients.
35. Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector
36. Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LC–MS.
37. Structural insight and stability of TNFR-Fc fusion protein (Etanercept) produced by using transgenic silkworms.
38. Highly sensitive HPLC analysis and biophysical characterization of N‐glycans of IgG‐Fc domain in comparison between CHO and 293 cells using FcγRIIIa ligand.
39. Recent Achievements and Current Interests in Research on the Characterization and Quality Control of Biopharmaceuticals in Japan.
40. Generic MS-based method for the bioanalysis of therapeutic monoclonal antibodies in nonclinical studies.
41. Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies.
42. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
43. Characterization of glycoengineered anti-HER2 monoclonal antibodies produced by using a silkworm-baculovirus expression system.
44. Development and characterization of an anti-rituximab monoclonal antibody panel.
45. Efficacy of oral cholecalciferol on rhododendrol‐induced vitiligo: A blinded randomized clinical trial.
46. Occludin as a functional marker of vascular endothelial cells on tube-forming activity.
47. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.
48. Recent Topics of Research in the Characterization and Quality Control of Biopharmaceuticals in Japan.
49. Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.
50. Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.